Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 1, 2003, Pages 80-91

  Lakhtakia, Ritu ^a   Kumar, Vijay ^b   Reddi, Honey ^b   Mathur, Meera ^a   Dattagupta, Siddhartha ^a   Panda, Subrat Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Experimental hepatocarcinogenesis; Hepatitis B virus; Transgenesis

Indexed keywords

LIVER ENZYME; MYC PROTEIN; PROTEIN P53; SCLEROPROTEIN; SUCCINATE DEHYDROGENASE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; IMMUNOPHENOTYPING; LATENT PERIOD; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ULTRASTRUCTURE;

EID: 12244281113     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.02902.x     Document Type: Article

References (56)

1. Parkin DM, Laara E, Muir CS. Estimation of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 1988; 41: 184-97.
2. Chen PJ, Chen DS. Hepatitis B virus and hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997; 29-38.
3. Koike K. Hepatitis B virus HBx gene and hepatocarcinogenesis.Intervirology 1995; 38: 134-42.
4. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JH, eds.Viral Hepatitis and Liver Disease. Orlando: Grune & Stratton, 1984; 209-24.
5. Beasley RP, Lin CC, Hwang LY, Chen CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129-33.
6. Beasley RP. Hepatitis B virus. The major etiology of hepa-tocellular carcinoma. Cancer 1988; 61: 1942-55.
7. Brechot C, Pourcel C, Louse A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286: 533-5.
8. Koshy R, Maupas P, Muller R, Hofschneider PH. Detection of hepatitis B virus specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues. J. General Virol. 1981; 57: 95-102.
9. Hohne M, Schafer S, Feitelsen MA, Paul D, Gerlich WH. Malignant transformation of immortalised transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J. 1990; 9: 1137-45.
10. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-45.
11. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 1998; 188: 341-50.
12. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hof-schneider PH, Koshy R. The pre S/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990; 343: 457-61.
13. Kumar V, Jayasuryan N, Kumar R. A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc. Natl. Acad. Sci. USA 1996; 93: 5647-62.
14. Gordon JW, Scangos GA, Plotkin DJ, Barbose JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. USA 1980; 77: 7380-4.
15. Koike K, Moriya K, Iino Set al. High level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19: 810-19.
16. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-20.
17. Terradillos O, Billet U, Renard CAet al. The hepatitis B virus X gene potentiates c-myc induced liver oncogenesis in transgenic mice. Oncogene 1997; 14: 395-404.
18. Yu D-Y, Moon H-B, Son J-K et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. Hepatol. 1999; 31: 123-32.
19. Singh M, Gulati N, Mandal Aet al. A tumor progression transgenic mouse model of hepatocellular carcinoma. In: Jameel S, Villarreal L, eds. Advances in Animal Virology. New Delhi: Oxford and IBH Publishing Co., 2000; 247-63.
20. Bancroft DJ, Stevens A, Turner DR.Theory and Practice of Histological Techniques, 4th Edn. New York: Churchill Livingstone, 1996; 135-6, 185-6, 194.
21. Lillie RD. Histopathological Technique and Practical Histochemistry. London: McGraw-Hill Co., 1954; 300-32.
22. Wachstein M, Meisel E. On the histochemical demonstration of glucose 6 phosphate. J. Histochem. Cytochem. 1956; 4: 592-94.
23. Nachlas MM, Tsau KC, De Souza E, Chang CS, Seligman AN. Cytochemical demonstration of succinic dehydrogenase by the use of a new p-nitrophenyl substituted ditetrazole. J. Histochem. Cytochem. 1957; 5: 420.
24. Horwitz C, Benitez L, Bray M. The effect of coenzyme Q on the histochemical succinic tetrazolium reductase reaction. J. Histochem. Cytochem. 1967; 15: 216-24.
25. Wachstein M, Meisel E. Histochemistry of hepatic phosphatases at a physiological pH. Am. J. Clin. Pathol. 1957; 27: 13-23.
26. Gomori G. Alkaline phosphatase of cell nuclei. J. Lab. Clin. Med. 1951; 37: 526-31.
27. Gomori G. Distribution of acid phosphatase in the tissues under normal and under pathologic conditions. Arch. Pathol. 1941; 32: 189-99.
28. Desmet VJ. The hazard of acid differentiation in Gomori's method for acid phosphatase. Stain Technol. 1962; 37: 373-76.
29. Pearse AGE. Histochemistry Theoretical and Applied, 3rd Edn; Vol. 2. Edinburgh: Churchill Livingstone, 1972.
30. Gordon JW. Transgenic animals. Int. Rev. Cytol. 1989; 115: 171-230.
31. Rubin EM, Barsh GS. Molecular medicine in genetically engineered animals. J. Clin. Invest. 1996; 97: 275-80.
32. Gordon JW, ed. Transgenic mouse models of hepatocellular carcinoma. Hepatology 1994; 19: 538-9.
33. Chisari FV, Klopchin KM, Moriyama T et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-56.
34. Reifenberg K, Lohler J, Pudollek HP et al. Long-term expression of the hepatitis B virus core-, e- and X protein does not cause pathologic changes in transgenic mice. J. Hepatol. 1997; 26: 119-30.
35. Lee Th, Finegold MJ, Shen RF, DeMayo JL, Woo SLL, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J. Virol. 1990; 64: 5939-47.
36. Hildt E, Hofschneider PH. The Pre S2 activation of the hepatitis B virus: Activation of tumor promoter pathways. Recent Results Cancer Res. 1998; 154: 315-29.
37. Chisari FU. Hepatitis B virus transgenic mice; insights into the virus and the disease. Hepatology 1995; 22: 1316-25.
38. Klein WP, Schneider RJ. Activation of the src family kinases by hepatitis B virus HBx protein and coupled signalling to Ras. Mol. Cell Biol. 1997; 17: 6427-36.
39. Shiota G, Kawasaki H, Nakamura T, Schmidt EV. Characterisation of double transgenic mice expressing hepatocyte growth factor and transforming growth factor alpha. Res. Commun. Mol. Pathol. Pharmacol. 1995; 90: 17-24.
40. Pollicino T, Terradillos O, Lecoeur H, Gougeon ML, Buendia MA. Proapoptotic effect of the hepatitis B virus X gene. Biomed. Pharmacother. 1998; 52: 363-8.
41. Huang SN, Chisari FV. Strong sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1997; 21: 620-6.
42. Liu P, Terradillos O, Renard CA, Felmann G, Buendia MA, Bernman D. Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: Sustained cell proliferation and biphasic activation of insulin-like growth factor II. Hepatology 1997; 25: 874-83.
43. Koike K, Moriya K, Yotsuyanagi H et al. Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis. Cancer Lett. 1998; 134: 181-6.
44. Terradillos O, Pollicino T, Lecoeur H et al. p53 independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 2115-23.
45. Snibson KJ, Bhathal PS, Hardy CL, Brandon MR, Adams TE. High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver 1999; 19: 242-52.
46. Bennoun M, Rissel M, Engelhardt N, Guillouzo A, Briand P, Weber-Benarous A. Oval cell proliferation in early stages of carcinogenesis in Simian virus 40 large T transgenic mice. Am. J. Pathol. 1993; 143: 1326-36.
47. Hully JR, Su Y, Lohse JK et al. Transgenic hepatocarcinogenesis in the rat. Am. J. Pathol. 1994; 145: 384-97.
48. Livini N, Ahamed E, Ilan Y et al. p53 expression in patients with cirrhosis with or without hepatocellular carcinoma. Cancer 1995; 75: 2420-6.
49. Yumoto Y, Hanafusa T, Hada H et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1995; 10: 179-85.
50. Yin L, Ghebranious N, Chakraborty S, Sheehan CE, Ilic Z, Sell S. Control of mouse hepatocyte proliferation and ploidy by p53 and p53 ser 246 mutation in vivo. Hepatology 1998; 27: 73-80.
51. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998; 27: 383-91.
52. Ueda H, Ulrich HJ, Gaugein JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995; 9: 41-7.
53. Kajino K, Kamiya N, Yusa S et al. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: Application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy. Biochem. Biophys. Res. Commun. 1997; 241: 43-8.
54. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997; 71: 3236-43.
55. Merle P, Levy R, Vitvitski L, Chevallier M, Buendia MA, Treyso L. Efficacy of interferon alpha in primary prevention of preneoplastic lesions in a transgenic mouse model of hepatocellular carcinoma related to the interaction between woodchuck hepatitis viruses and c-myc oncogene. Gastroenterol. Clin. Biol. 1997; 21: 459-65.
56. Moriya K, Matsukura M, Kurokawa K, Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem. Biophys. Res. Commun. 1996; 218: 217-23.